Literature DB >> 2757899

Pharmacokinetics of intravenous cilazaprilat in normal volunteers.

E M Whitehead1, G E Walters, P E Williams, G D Johnston.   

Abstract

The pharmacokinetics of 1 mg, 2 mg and 4 mg of cilazaprilat administered intravenously were determined in a group of eight volunteers. The fall in plasma concentration was polyphasic. Elimination was predominantly by renal excretion of the unchanged drug. The mean renal clearance values following 1 mg, 2 mg and 4 mg doses were 5.3 +/- 0.5, 8.1 +/- 0.5, and 9.8 +/- 0.5 l h-1 and plasma clearances were 7.8 +/- 0.5, 10.4 +/- 0.5 and 11.8 +/- 0.6 l h-1, respectively. Thus, plasma and renal clearances were dose dependent. ACE inhibition was greater than 82% for the first 4 h and about 55% at 24 h, after all three doses. There were no significant haemodynamic effects at any dose.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757899      PMCID: PMC1379818          DOI: 10.1111/j.1365-2125.1989.tb03453.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.

Authors:  R J Francis; A N Brown; L Kler; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

2.  Disposition of fosinopril sodium in healthy subjects.

Authors:  S M Singhvi; K L Duchin; R A Morrison; D A Willard; D W Everett; M Frantz
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

3.  Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.

Authors:  I L Natoff; J S Nixon; R J Francis; L R Klevans; M Brewster; J Budd; A T Patel; J Wenger; E Worth
Journal:  J Cardiovasc Pharmacol       Date:  1985 May-Jun       Impact factor: 3.105

4.  Enalapril maleate and a lysine analogue (MK-521): disposition in man.

Authors:  E H Ulm; M Hichens; H J Gomez; A E Till; E Hand; T C Vassil; J Biollaz; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

5.  Captopril kinetics.

Authors:  K L Duchin; S M Singhvi; D A Willard; B H Migdalof; D N McKinstry
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

6.  Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers.

Authors:  T Fasanella d'Amore; J P Bussien; J Nussberger; B Waeber; G A Turini; H R Brunner; L Kler; R J Francis
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

  6 in total
  4 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Pharmacokinetics of cilazapril in patients with renal failure.

Authors:  J P Fillastre; B Moulin; M Godin; P E Williams; A N Brown; R J Francis; P Pinta; R Manfredi
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

4.  The pharmacokinetics and bioavailability of cilazapril in normal man.

Authors:  P E Williams; A N Brown; S Rajaguru; R J Francis; G E Walters; J McEwen; C Durnin
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.